MIR1249: MIR1249 is one of the top up-regulated genes in the study [PMC9279949]. It has been validated in different time points [PMC6006352]. Down-regulation of Dicer leads to decreased production of MIR1249 [PMC3316564]. MIR1249 inhibition can increase chemo-sensitivity by limiting the expansion of chemo-refractory cancer stem cells (CSCs) [PMC7590111]. MIR1249 is associated with the Wnt signaling pathway [PMC7590111]. MIR1249 expression is increased in response to chemotherapy treatment in human cholangiocarcinoma (CCA) cells [PMC7590111]. Inhibition of MIR1249 reduces the enrichment of CD133+ cells, while its enforced expression reduces sensitivity to chemotherapy [PMC7590111]. MIR1249 plays a role in driving the expansion of CSCs and is associated with worse prognosis independently of adjuvant chemotherapy in BTC patients [PMC7590111]. CD133+ BTC cells express higher levels of MIR1249 compared to CD133- cells, and its inhibition enhances BTC cell response to chemotherapy treatment [PMC7590111]. FZD8 is a potential target gene regulated by MIR1249, and its inhibition recapitulates the phenotype induced by MIR1249 mimic [PMC7590111].\n\nReferences:\n- PMC9279949\n- PMC6006352\n- PMC3316564\n- PMC7